AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022

10 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

22 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

13 Dec 2021 18:15:00 By Nasdaq GlobeNewswire

Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition

13 Dec 2021 10:30:00 By Nasdaq GlobeNewswire

Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Agios Appoints Richa Poddar as Chief Commercial Officer

15 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition

04 Nov 2021 09:00:01 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and Third Quarter 2021 Financial Results

03 Nov 2021 07:10:58 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021

21 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Agios To Present at September Investor Conferences

30 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

17 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and Second Quarter 2021 Financial Results

29 Jul 2021 07:00:03 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021

15 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

28 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency

22 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

21 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress

11 Jun 2021 03:00:00 By Nasdaq GlobeNewswire

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress

11 Jun 2021 03:00:00 By Nasdaq GlobeNewswire

Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress

12 May 2021 10:00:00 By Nasdaq GlobeNewswire